Phase 1 trial 177Lu-IM-3050 radiopharmaceutical advanced solid malignancies
Summary
The National Library of Medicine registered a new Phase 1 clinical trial (NCT07505771) on ClinicalTrials.gov evaluating 177Lu-IM-3050 radiopharmaceutical in patients with advanced solid malignancies. The dose-escalation study represents an informational registry entry documenting ongoing clinical research activity.
What changed
A new Phase 1 clinical trial has been registered on ClinicalTrials.gov for 177Lu-IM-3050, a radiopharmaceutical agent, for the treatment of advanced solid malignancies. The trial is identified as NCT07505771 and is structured as a dose-escalation study to evaluate safety and tolerability. This is an informational registry entry without regulatory mandates or compliance requirements.
Healthcare providers and patients interested in trial participation should review full eligibility criteria and site locations on ClinicalTrials.gov. Sponsors conducting similar radiopharmaceutical research should ensure timely registration per applicable requirements. No specific compliance actions or deadlines apply to this registry entry.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Show glossary
Related changes
Get daily alerts for ClinicalTrials.gov
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NLM.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov publishes new changes.